Al's Comment:

 Can a Gut-Derived Compound Make Immunotherapy Work Better?

 

One of the biggest frustrations with cancer immunotherapy is that, while treatments such as checkpoint inhibitors can produce dramatic responses in some patients, they do very little for many others. Researchers at the University of Michigan may have found an interesting way to improve those odds.

 

They developed an oral nanomedicine based on 3,4-dihydroxybenzoic acid (DHB), a natural compound produced by gut bacteria when dietary fiber is broken down. DHB appears to help T cells maintain a more durable, “memory-like” state instead of becoming exhausted and losing their ability to attack cancer.

 

Because DHB itself is poorly absorbed and quickly eliminated, the researchers converted it into a prodrug and packaged it in a nanoemulsion designed to improve delivery. In mouse models of melanoma, colorectal cancer and breast cancer, combining the oral treatment with checkpoint inhibitors eradicated tumors and generated immune memory that protected against recurrence. The treatment also improved the activity of CAR T-cell therapy.

 

For the brain tumor community, the concept is particularly interesting. Glioblastoma has historically responded poorly to checkpoint inhibitors, in part because its immune environment suppresses T-cell activity. Anything capable of keeping T cells functional longer could potentially help immunotherapies work better.

 

However, there is an important caveat: this research has so far been demonstrated in mice, not patients, and glioblastoma was not one of the tumor models reported in this study. We have seen many promising immunotherapy approaches cure tumors in mice only to disappoint in human trials.

 

Still, I think this is an intriguing avenue of research. Instead of inventing an entirely new immune therapy, researchers may be able to make existing treatments work better by changing the metabolic environment of the immune cells themselves. If this approach translates to humans, combinations with checkpoint inhibitors, vaccines, CAR T cells or other immune therapies could eventually be worth exploring in brain tumors.

 

As always, the next important step is human clinical testing.

https://www.michiganmedicine.org/health-lab/new-oral-nanomedicine-boosts-effectiveness-cancer-immunotherapies